All Posts Tagged With: "ALKS"
(ALKS) Alkermes Drug Application Gets New Target Date
Recently, the U.S. Food and Drug Administration (FDA) announced that inclement weather has forced the agency to delay the review of the new drug application (NDA) of the type II diabetes candidate, exenatide once-weekly.
Exenatide once-weekly is co-developed by Alkermes...
(ALKS) Alkermes Pipeline Announces Good News
Recently, Alkermes Inc. (ALKS) announced encouraging topline data from an early-stage study of its candidate of ALKS 37. ALKS 37 is an orally active, peripherally-restricted opioid antagonist having the potential...
(ALKS) Alkermes Retains Neutral Recommendation
We maintain our Neutral rating on Alkermes, Inc. (ALKS) with a price target of $11.50.
Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies...
(ALKS) Alkermes Reports Lower Third Quarter Loss
Alkermes Inc. (ALKS) reported a third quarter fiscal 2010 net loss of 3 cents per share (excluding items but including stock based compensation) compared with a loss of 9 cents in the year-ago period (excluding...
(RX) Pharma & Biotech Stock Review – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a...
(AMLN) Amylin Pharmaceuticals Impresses in Head-to-Head
Amylin Pharmaceuticals, Inc. (AMLN) recently announced positive results on its once weekly formulation of Byetta (referred to as exenatide once weekly), which is being developed in collaboration with Eli...
(ALKS) Good News for Alkermes’ Drug Pipeline
Recently, Alkermes Inc. (ALKS) announced that its drug Vivitrol, which is indicated for the treatment of alcohol dependence, also helped opioid addicts stay away from drugs. Data from the six-month late-stage...
(ALKS) Alkermes Moves to Loss but Beats Consensus Estimates
Alkermes, Inc. (ALKS) reported a second quarter fiscal 2010 net loss of 5 cents per share, compared with a profit of 2 cents in the year-ago period. The Zacks Consensus Estimate was a loss of 10 cents.
Revenues...
(RX) Big Pharma and Biotech – Industry Outlook
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance...
(ALKS) Good News for Alkermes’ Drug Pipeline
Recently, Alkermes Inc. (ALKS) announced that its pipeline candidate, ALKS33, for addiction and nervous system disorders, gave positive results in two early stage clinical trials. Results from the two studies, ALK33-003 and ALK33-004, demonstrated that the...
(AMLN) Amylin Amylin Pharmaceuticals Collaborates with Biocon
Yesterday, Amylin Pharmaceuticals, Inc. (AMLN) entered into an exclusive agreement with Indian biotech company Biocon Limited for the development, commercialization and manufacture of a novel peptide therapeutic for the potential treatment of diabetes.
This...
(ALKS) Alkermes Notified Johnson & Johnson Intends to Stop Development of Risperidone
On Wednesday, Alkermes, Inc. (ALKS) disclosed that it has received notification from Johnson & Johnson’s (JNJ) Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International stating that Janssen does not intend to...
(MYGN) Biotech Industry – Zacks Analyst Interviews
OVERVIEW
The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ...
(WYE) Biotech Industry – Industry Outlook
OVERVIEW
The financial market and the economic landscape in the U.S. have not changed much since the beginning of the year. And we believe the status quo will last for a while at least in 2009.
Large biotech companies are doing OK since they...